| Benazepril hydrochloride is the3rd generation of angiotensin converting enzyme inhibitors (ACEI) and its main mechanism of action is inhibition of angiotensin-converting enzyme (ACE), thereby reducing the concentration of plasma angiotensin Ⅱ (Ang) to achieve the treatment of heart failure, hypertension and so on. Clinically it is widely used in the treatment of the heart failure, hypertension, chronic renal insufficiency. This article explore the safety of benazepril hydrochloride from the following aspects, and evaluate its remedial effects on the treatment of the canine congestive heart failure and then provide guidance for its application in the pet clinic.Test I Safety of Benazepril hydrochloride in canineThe test was conducted to evaluate the safety of benazepril hydrochlorides in canine. Twenty four healthy adult dogs about10kg were selected and randomly divided into four groups of six. According to the recommended clinical dose of the drug (0.5mg.kg-1), they are respectively set0times the recommended clinical dosage group (0mg.kg-1).the recommended clinical dosage group (0.5mg.kg-1),3times the recommended clinical dosage group (1.5mg.kg-1),5times the recommended clinical dosage group (2.5mg.kg-1). Administered once daily for consecutive9weeks. Clinical manifestations were observed. Hematological, blood biochemical and electrolyte parameters, urinalysis and pathological changes were compared on the day before the test,2,4,6,9weeks after administered and2nd week after discontinuation. The result shows that there is no significant difference among0times the recommended clinical dosage group and the recommended clinical dosage group,3times the recommended clinical dosage group and5times the recommended clinical dosage group (P>0.05).Test Ⅱ The establishment of the canine congestive heart failure modelTwenty one healthy adult dogs about5kg were selected, and taked the before-after study. To establish the canine congestive heart failure model by combing abdominal aortic stenosis with hypodermic injection the epinephrine hydrochloride. Specific methods: epinephrine hydrochloride were given hypodermic injection after two weeks with the abdominal aortic stenosis,3mg.kg-1for consecutive3weeks.Clinical symptoms were observed throughout the trial period.Blood biochemical and serum electrolytes parameters changes were compared on the day before the test, two weeks after the abdominal aortic stenosis,1th week to3th after administered and2nd week after discontinuation,and the results of the chest X-ray before and after the test were compared.Results:18dogs were successfully established model of the level III congestive heart failure,and symptoms such as cough, visible mucosal cyanosis, arrhythmia became increasingly obvious as administration time prolonged and had no improvement after2weeks discontinued; the concentration of LDH,CK and AST increased significantly during the use of epinephrine,and were lower in the2weeks off,but were higher than before the test and the difference was significant (P<0.05).The serum electrolytes indicators have no apparent change; after the test,18dogs’ VHS value had significantly difference (P<0.05). The result shows that abdominal aortic stenosis combined with hypodermic injection the epinephrine hydrochloride allows rapid establishment of a reliable canine model of congestive heart failure.Test III Clinical efficacy of benazepril hydrochloride in canine with congestive heart failureTo explore the therapeutic effect of benazepril hydrochloride in canine congestive heart failure,18congestive heart failure dogs were randomly divided into three groups of six. Three groups were setted:the blank control group without medicine, the pimobendan group and the benazepril hydrochloride group. The drug therapy groups were administered respectively for4weeks. Through the observation of clinical symptoms, results of blood, blood biochemistry, electrolytes, and chest X-ray to assess the effect of benazepril hydrochloride on the treatment of canine congestive heart failure.Results:No significant difference in each test groups of their the hematology and the electrolyte parameters(p>0.05); compared the drug therapy groups with the control group, there was significant difference in the result of LDH,CK and AST (p<0.05),but the difference between the two administration groups was not noteworthy (p>0.05);Clinical performance score between the drug treatment group with the control group is significant difference (p<0.05); there is67%(4/6)excellence,33%(2/6)advance,0(0/6)inefficiency in the the benazepril hydrochloride group, and the total effective rate was100%(6/6). There was no significant difference with pimobendan treatment group. Though the whole test, no drug-related adverse reactions appeared. The results suggest that benazepril hydrochloride for canine congestive heart failure, have better effect for treatment of consecutive4weeks. |
